

TRAmetinib In Neurofibromatose type 1 related symptomatic plexiform neurofibroma

Gepubliceerd: 27-09-2019 Laatste bijgewerkt: 18-08-2022

Trametinib can induce shrinkage in neurofibromatosis type 1 related plexiform neurofibromas. Response to treatment is defined as a tumor volume decreases from baseline of $\geq 20\%$, monitored by using volumetric MRI analysis.

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON28237

Bron

Nationaal Trial Register

Verkorte titel

TRAIN

Aandoening

Neurofibromatosis type 1, NF1, plexiform neurofibroma

Ondersteuning

Primaire sponsor: Erasmus MC

Overige ondersteuning: Stichting NF and Novartis

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Toelichting onderzoek

Achtergrond van het onderzoek

Rationale: Neurofibromatosis type 1 (NF1) is one of the most common neuro-genetic diseases. Approximately half of the patients with NF1 have plexiform neurofibromas (PNF).¹ Besides severe cosmetic problems, the PNF cause neurological deficit, severe pain and a 8-12% lifetime risk of developing a Malignant Peripheral Nerve Sheath Tumor (MPNST).^{2, 3} Up till now surgery is the only standard treatment option for PNF. Complete resection is often impossible due to extensive and invasive growth of the PNF. Therefore, systemic treatment options for PNF in NF1 are a highly unmet medical need.

Recent data suggests that children with inoperable neurofibromatosis type 1 related PNF benefited from long-term treatment with an oral selective inhibitor of MAPK kinase (MEK) 1 (selumetinib) without having excess toxic effects.⁴ Treatment with selumetinib resulted in a response rate of 71% in 24 children. Following this observation we now propose to perform a study with trametinib, a MEK1/2 inhibitor, in adult NF1 patients with symptomatic PNF.

Objective: Primary objective: Response to trametinib treatment defined as a tumor volume decreases from baseline of $\geq 20\%$, monitored by using volumetric MRI analysis. Secondary objectives are: patient reported outcomes of pain and disability and quality of life, the effect of trametinib on disfigurement, safety and tolerability of trametinib, the duration of response and the incidence of surgical interventions

Study design: This is a non-randomized, open-label, single arm phase 2 study to determine whether we can achieve a response for NF1 patients with symptomatic PNF using trametinib.

Study population: 30 adult patients (age >17 years) with (mosaic) NF1 with inoperable symptomatic plexiform neurofibromas

Intervention: Trametinib 2mg daily, orally, continuous until progression

Main study parameters/endpoints: The primary endpoint is response to treatment defined as a tumor volume decreases from baseline of $\geq 20\%$

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Generally, the side-effects of trametinib are mild and manageable. The main burden for the patients are 4 weekly visits during therapy and every 3 months thereafter until progression. Blood samples will be taken every 4 weeks during therapy. 6 monthly a MRI, quality of life forms and physical examination will be done until progression. Needle biopsies from the (largest) index PNF will be performed pre-treatment and at 12 weeks. A needle biopsy is minimally invasive and is typically a safe procedure.

Doel van het onderzoek

Trametinib can induce shrinkage in neurofibromatosis type 1 related plexiform neurofibromas. Response to treatment is defined as a tumor volume decreases from baseline of $\geq 20\%$, monitored by using volumetric MRI analysis.

Onderzoeksopzet

Disease will be assessed by volumetric MRI every 24 weeks until documented progression. Safety profile of the treatment will be assessed every 4 weeks during therapy and every 3 months after the end of treatment. Furthermore, quality of life assessments takes place every 24 weeks using questionnaires.

Onderzoeksproduct en/of interventie

Trametinib 2mg daily, orally, continuous until progression, patients refusal to continue the medication with trametinib or unacceptable side effects of trametinib.

Contactpersonen

Publiek

Erasmus MC Cancer Institute
Walter Taal

+31 10 7041415

Wetenschappelijk

Erasmus MC Cancer Institute
Walter Taal

+31 10 7041415

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Patient with (mosaic) NF1
2. Patients with a clinically significant symptomatic plexiform neurofibroma (PNF), such as (but not limited to) head and neck lesions that could compromise the airway or great vessels, brachial or lumbar plexus lesions that could cause nerve compression and loss of function, lesions that could result in major deformity (e.g., orbital lesions) or are significantly disfiguring, lesions of the extremity that cause limb hypertrophy or loss of function, and painful lesions. This will be determined by the treating physician.

3. Signed, written informed consent
4. Age: 18 or higher
5. Karnofsky performance level of $\geq 70\%$
6. No standard treatment options = inoperable PNF
PNF that cannot be surgically completely removed without risk for substantial morbidity due to invasiveness, high vascularity or encasement of, or close proximity to, vital structures of the PNF.
7. At least one measurable PNF, defined as a well-demarcated lesion of at least 3 cm measured in one dimension.
8. Able to swallow and retain orally administered medication.
9. Female Subjects of Childbearing Potential must have negative pregnancy test within 7 days prior study treatment and agrees to use highly effective contraception
10. Normal hematological function: Hemoglobin (Hb) ≥ 6 mmol/l, absolute neutrophil count (ANC) $\geq 1.5 \times 10^9/l$, and platelets $\geq 100 \times 10^9/l$
11. Normal hepatic function: bilirubin $< 1.5 \times$ the upper limit of normal (UNL), unless gilbert then: bilirubin $< 3 \times$ UNL and AST/ALT $< 5 \times$ UNL
12. Normal renal function: creatinine $< 1.5 \times$ UNL

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Prior treatment with MEK inhibitor(s)
2. Inability to undergo MRI and/or contraindication for MRI examinations
3. History of a malignancy within 5 years of inclusion, except squamous cell carcinoma of the skin, cervical premalignant lesions and other curatively treated malignancy
4. Prior radiotherapy less than 6 weeks prior to enrollment
5. Prior major surgery less than 4 weeks prior to enrollment
6. An investigational agent within the past 30 days.
7. Enzyme-inducing anticonvulsants, anti-coagulants (including platelet aggregation inhibitors) or other prohibited medication(s) or requirement for prohibited medications
8. Left ventricular dysfunction, New York Heart Association Class II, III, or IV heart failure, acute coronary syndrome within the past 6 months, clinically significant uncontrolled arrhythmias, and uncontrolled hypertension.
9. A history of retinal vein occlusion (RVO) or predisposing factors for RVO, including uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or a history of hyperviscosity or hypercoagulability syndromes
10. Risk factors for gastrointestinal perforation, including history of diverticulitis, metastases to the gastrointestinal tract and concomitant use of medications with a recognized risk of gastrointestinal perforation
11. Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses, or renal transplant, including any patient known to have hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) will be excluded.
12. Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption.
13. Any serious and/or unstable pre-existing medical disorder, psychiatric disorder, or other

conditions that could interfere with subject's safety

14. Known severe hypersensitivity to trametinib or any excipient of trametinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib

15. Pregnant, lactating or actively breastfeeding female subjects

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Anders
Toewijzing:	N.v.t. / één studie arm
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	07-07-2020
Aantal proefpersonen:	30
Type:	Verwachte startdatum

Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

Wordt de data na het onderzoek gedeeld: Nee

Toelichting

N/A

Ethische beoordeling

Positief advies	
Datum:	27-09-2019
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL8050
Ander register	METC Erasmus MC : MEC-2019-0463

Resultaten

Samenvatting resultaten

N/A